Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating an all-oral regimen of ombitasvir/paritaprevir/ritonavir with or without dasabuvir and with or without ribavirin in adults with chron…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Hepatocellular Carcinoma

Drugs mentioned

• Dasabuvir (dasabuvir)
• Ombitasvir (ombitasvir)
• Paritaprevir (paritaprevir)
• Ribavirin (ribavirin)
• Ritonavir (Ritonavir)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C Infection | Phase 3 | Status: TERMINATED | Results posted: 2017-12-12